Kathryn C. Arbour

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi, Francisco Sánchez-Vega, Konnor La et al. · Journal of Clinical Oncology · 2018 · 1.4K citations · Full text

Medicine, Immunology, Oncology +17

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

Kathryn C. Arbour, Laura Mezquita, Niamh M. Long et al. · Journal of Clinical Oncology · 2018 · 1.1K citations · Full text

Pharmacy, Oncology, Pharmacology +17

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Lisa Derosa, Matthew D. Hellmann, Marco Spaziano et al. · Annals of Oncology · 2018 · 871 citations · Full text

Medicine, Immunology, Oncology +17

<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane et al. · Journal of Clinical Oncology · 2018 · 471 citations

Medicine, Oncology, Pathology +17

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

Kathryn C. Arbour, Emmett Jordan, Hyunjae R. Kim et al. · Clinical Cancer Research · 2017 · 460 citations

Medicine, Genetics, Oncology +16